Sauvageau Chantal, Duval Bernard, Gilca Vladimir, Lavoie France, Ouakki Manale
Quebec Regional Public health department, Health and Social Services Agency, Quebec, Canada.
BMC Public Health. 2007 Oct 25;7:304. doi: 10.1186/1471-2458-7-304.
The Pap test has been used for cervical cancer screening for more than four decades. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is commercially available now. These two preventive interventions should be considered simultaneously. General population support is an important factor for the successful combination of these interventions. The study had two objectives: 1) To assess practices, beliefs, and attitudes regarding Pap test screening and HPV immunization; 2) To identify socio-demographic factors for Pap screening and vaccine acceptability.
In 2006, 500 adults were invited to participate in a telephone survey in the region of Quebec City (urban and rural population, 600 000), Canada. Some neutral and standardized information on Pap test and HPV was provided before soliciting opinions.
471 adults (18-69 year-olds) answered the questionnaire, the mean age was 45 years, 67% were female, and 65% had college or university degree. Eighty-six percent of women had undergone at least one Pap-test in their life, 55% in the last year, and 15% from 1 to 3 years ago. Among screened women, the test had been performed in the last three years in 100% of 18-30 year-olds, but only in 67% of 60-69 year-olds (P < 0.0001). Only 15% of respondents had heard of HPV. Eighty-seven percent agreed that HPV vaccines could prevent cervical cancer, 73% that the vaccine has to be administered before the onset of sexual activity, 89% would recommend vaccination to their daughters and nieces. Among respondents < 25 years, 91% would agree to receive the vaccine if it is publicly funded, but only 72% would agree to pay $100/dose.
There is an important heterogeneity in cervical cancer screening frequency and coverage. Despite low awareness of HPV infection, the majority of respondents would recommend or are ready to receive the HPV vaccine, but the cost could prevent its acceptability.
巴氏试验用于宫颈癌筛查已逾四十载。人乳头瘤病毒(HPV)疫苗已在加拿大获批使用且现已有售。这两种预防性干预措施应同时加以考虑。公众支持是这些干预措施成功结合的重要因素。该研究有两个目标:1)评估关于巴氏试验筛查和HPV免疫接种的做法、信念及态度;2)确定巴氏筛查和疫苗可接受性的社会人口学因素。
2006年,邀请500名成年人参与在加拿大魁北克市地区(城乡人口共60万)进行的电话调查。在征求意见前提供了一些关于巴氏试验和HPV的中立且标准化的信息。
471名成年人(年龄在18 - 69岁之间)回答了问卷,平均年龄为45岁,67%为女性,65%拥有大专或本科学历。86%的女性一生中至少接受过一次巴氏试验,55%在过去一年接受过,15%在1至3年前接受过。在接受筛查的女性中,18 - 30岁的女性100%在过去三年进行过该项检查,而60 - 69岁的女性中只有67%(P < 0.0001)。只有15%的受访者听说过人乳头瘤病毒。87%的人同意HPV疫苗可预防宫颈癌,73%的人认为该疫苗必须在开始性行为之前接种,89%的人会向其女儿和侄女推荐接种疫苗。在年龄小于25岁的受访者中,91%的人表示如果疫苗由公共资金资助,他们会同意接种,但只有72%的人会同意支付每剂100美元。
宫颈癌筛查频率和覆盖范围存在重要的异质性。尽管对HPV感染的知晓率较低,但大多数受访者会推荐或愿意接种HPV疫苗,不过成本可能会影响其可接受性。